Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Loratadine and Famotidine Combination on Preventing Filgrastim-Induced Bone Pain in Breast Cancer Patients

NCT06265077 is registered in ClinicalTrials.gov with Noha Mansour as lead sponsor.

NCT NCT06265077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06265077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Loratadine and Famotidine Combination on Preventing Filgrastim-Induced Bone Pain in Breast Cancer Patients
Lead sponsor
Noha Mansour
Phase
Phase 1/2
Overall status
Completed
Start date
February 1, 2024
Completion date
October 17, 2024
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, filgrastim adverse reaction